Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Catherine Thiéblemont(Université Paris Cité), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Tatyana Feldman(Hackensack University Medical Center), Kim Linton(The Christie NHS Foundation Trust), Marjolein van der Poel(Maastricht University), David Soong(Genmab (United States)), Yasmin Karimi(Michigan Medicine), Minh H Dinh(AbbVie (United States)), David Cunningham(Royal Marsden NHS Foundation Trust), Tycel Phillips(Michigan Medicine), Martin Hutchings(University of Copenhagen), Chan Y. Cheah(The University of Western Australia), Robin Gasiorowski(The University of Sydney), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Hervé Ghesquières(Université Claude Bernard Lyon 1), Nurgul Kilavuz(Princeton University), Tae Min Kim(Seoul National University Hospital), Wojciech Jurczak(Jagiellonian University), David Lewis(University Hospitals Plymouth NHS Trust), Mariana Sacchi(Genmab (United States)), Michelle Poon(National University Hospital), Michael Roost Clausen(Vejle Sygehus), Thomas Mark(Genmab (Denmark)), Young Rok(Keimyung University Dongsan Medical Center)
Cited by 132
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k